These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8721545)

  • 21. What's new, what's next?
    Fakuda D
    Posit Dir News; 1998; 10(2):1, 3-7, 10. PubMed ID: 11365547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two new protease inhibitors approved by FDA. Food and Drug Administration.
    Folkers G
    NIAID AIDS Agenda; 1996 Mar; ():4-5. PubMed ID: 11363799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ICAAC update.
    Coppedge B
    STEP Perspect; 1996; 8(3):15-6. PubMed ID: 11364265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ritonavir plus saquinavir: two trials with different results.
    Mascolini M
    AIDS Treat News; 1996 Sep; (No 254):5-6. PubMed ID: 11363819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.
    Poirier JM; Robidou P; Jaillon P
    Ther Drug Monit; 2005 Apr; 27(2):186-92. PubMed ID: 15795650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abbott agrees to expanded access for ritonavir.
    Baker R
    BETA; 1995 Sep; ():4. PubMed ID: 11362891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protease inhibitor trials moving to next phase.
    AIDS Alert; 1995 Aug; 10(8):100-1. PubMed ID: 11362675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
    Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
    AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protease inhibitors show promise in HIV infection.
    Nelson H
    Lancet; 1996 Feb; 347(8998):383. PubMed ID: 8598709
    [No Abstract]   [Full Text] [Related]  

  • 32. Ritonavir, saquinavir combination--& warning.
    AIDS Treat News; 1995 Sep; (no 231):6. PubMed ID: 11362871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro.
    Drusano GL; D'Argenio DZ; Symonds W; Bilello PA; McDowell J; Sadler B; Bye A; Bilello JA
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2153-9. PubMed ID: 9736527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage therapy with ritonavir-saquinavir plus two nucleoside reverse transcriptase inhibitors in patients failing with amprenavir-zidovudine-lamivudine.
    De Wit S; Cassano P; Hermans P; Kabeya K; Gerard M; O'Doherty E; Clumeck N
    AIDS; 1999 May; 13(7):864-5. PubMed ID: 10357390
    [No Abstract]   [Full Text] [Related]  

  • 36. Freedom of choice.
    Vazquez E
    Posit Aware; 1996; 7(3):9, 19. PubMed ID: 11363432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.
    Craig C; Race E; Sheldon J; Whittaker L; Gilbert S; Moffatt A; Rose J; Dissanayeke S; Chirn GW; Duncan IB; Cammack N
    AIDS; 1998 Sep; 12(13):1611-8. PubMed ID: 9764779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 protease inhibitors. A review for clinicians.
    Deeks SG; Smith M; Holodniy M; Kahn JO
    JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational approaches to resistance: using saquinavir.
    Boucher C
    AIDS; 1996 Nov; 10 Suppl 1():S15-9. PubMed ID: 8970671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.